Molecular imaging biomarkers for immune checkpoint inhibitor therapy
Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple dif...
Gespeichert in:
| Veröffentlicht in: | Theranostics 2020, Vol.10 (4), p.1708-1718 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1718 |
|---|---|
| container_issue | 4 |
| container_start_page | 1708 |
| container_title | Theranostics |
| container_volume | 10 |
| creator | van de Donk, Pim P Kist de Ruijter, Laura Lub-de Hooge, Marjolijn N Brouwers, Adrienne H van der Wekken, Anthonie J Oosting, Sjoukje F Fehrmann, Rudolf Sn de Groot, Derk Jan A de Vries, Elisabeth Ge |
| description | Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with
F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy. |
| doi_str_mv | 10.7150/thno.38339 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6993216</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2598255255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-95dce9b786d7577f9ba1b57345295efcf8cae18e8dde4fbe6a33bf69def29f003</originalsourceid><addsrcrecordid>eNpdkVFLHDEUhUNRumJ96Q8oA32RwtokdzIzeRFEa1tQfLHPIZO52YnOJGsyI_jvm3XtsjYEcsn5OJzLIeQzo2c1E_T71PtwBg2A_ECOWAPNsq5KerA3L8hJSg80n5JyyeRHsgBOSw7AjsjVbRjQzIOOhRv1yvlV0bow6viIMRU2bL7H2WNhejSP6-D8VDjfu9ZNWZt6jHr98okcWj0kPHl7j8mf6x_3l7-WN3c_f19e3CxNSatpKUVnULZ1U3W1qGsrW81aUUMpuBRojW2MRtZg03VY2hYrDdDaSnZoubSUwjE53_qu53bEbOanqAe1jjl6fFFBO_Ve8a5Xq_CsKimBsyobnL4ZxPA0Y5rU6JLBYdAew5wUBwGiliAho1__Qx_CHH1eT3EhGy5Evpn6tqVMDClFtLswjKpNP2rTj3rtJ8Nf9uPv0H9twF-GeI2p</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598255255</pqid></control><display><type>article</type><title>Molecular imaging biomarkers for immune checkpoint inhibitor therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>van de Donk, Pim P ; Kist de Ruijter, Laura ; Lub-de Hooge, Marjolijn N ; Brouwers, Adrienne H ; van der Wekken, Anthonie J ; Oosting, Sjoukje F ; Fehrmann, Rudolf Sn ; de Groot, Derk Jan A ; de Vries, Elisabeth Ge</creator><creatorcontrib>van de Donk, Pim P ; Kist de Ruijter, Laura ; Lub-de Hooge, Marjolijn N ; Brouwers, Adrienne H ; van der Wekken, Anthonie J ; Oosting, Sjoukje F ; Fehrmann, Rudolf Sn ; de Groot, Derk Jan A ; de Vries, Elisabeth Ge</creatorcontrib><description>Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with
F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.</description><identifier>ISSN: 1838-7640</identifier><identifier>EISSN: 1838-7640</identifier><identifier>DOI: 10.7150/thno.38339</identifier><identifier>PMID: 32042331</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher Pty Ltd</publisher><subject>Antibodies ; Apoptosis ; Biomarkers ; Biomarkers, Tumor - immunology ; Biomarkers, Tumor - metabolism ; Cancer ; Cytotoxicity ; Data warehouses ; FDA approval ; Fractals ; Humans ; Immune Checkpoint Inhibitors - metabolism ; Immune Checkpoint Inhibitors - therapeutic use ; Immunotherapy ; Immunotherapy - methods ; Ligands ; Lymphocytes ; Lymphoma ; Medical research ; Melanoma ; Metabolism ; Molecular Imaging - methods ; Neoplasms - diagnostic imaging ; Neoplasms - immunology ; Neoplasms - pathology ; Neoplasms - therapy ; Oncology ; Patient Selection ; Patients ; Positron-Emission Tomography - methods ; Review ; T-Lymphocytes - immunology ; Tomography ; Tomography, Emission-Computed, Single-Photon - methods ; Tumors ; Working groups</subject><ispartof>Theranostics, 2020, Vol.10 (4), p.1708-1718</ispartof><rights>The author(s).</rights><rights>2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-95dce9b786d7577f9ba1b57345295efcf8cae18e8dde4fbe6a33bf69def29f003</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993216/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993216/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,4024,27922,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32042331$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van de Donk, Pim P</creatorcontrib><creatorcontrib>Kist de Ruijter, Laura</creatorcontrib><creatorcontrib>Lub-de Hooge, Marjolijn N</creatorcontrib><creatorcontrib>Brouwers, Adrienne H</creatorcontrib><creatorcontrib>van der Wekken, Anthonie J</creatorcontrib><creatorcontrib>Oosting, Sjoukje F</creatorcontrib><creatorcontrib>Fehrmann, Rudolf Sn</creatorcontrib><creatorcontrib>de Groot, Derk Jan A</creatorcontrib><creatorcontrib>de Vries, Elisabeth Ge</creatorcontrib><title>Molecular imaging biomarkers for immune checkpoint inhibitor therapy</title><title>Theranostics</title><addtitle>Theranostics</addtitle><description>Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with
F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.</description><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - immunology</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Cytotoxicity</subject><subject>Data warehouses</subject><subject>FDA approval</subject><subject>Fractals</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - metabolism</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Medical research</subject><subject>Melanoma</subject><subject>Metabolism</subject><subject>Molecular Imaging - methods</subject><subject>Neoplasms - diagnostic imaging</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - therapy</subject><subject>Oncology</subject><subject>Patient Selection</subject><subject>Patients</subject><subject>Positron-Emission Tomography - methods</subject><subject>Review</subject><subject>T-Lymphocytes - immunology</subject><subject>Tomography</subject><subject>Tomography, Emission-Computed, Single-Photon - methods</subject><subject>Tumors</subject><subject>Working groups</subject><issn>1838-7640</issn><issn>1838-7640</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkVFLHDEUhUNRumJ96Q8oA32RwtokdzIzeRFEa1tQfLHPIZO52YnOJGsyI_jvm3XtsjYEcsn5OJzLIeQzo2c1E_T71PtwBg2A_ECOWAPNsq5KerA3L8hJSg80n5JyyeRHsgBOSw7AjsjVbRjQzIOOhRv1yvlV0bow6viIMRU2bL7H2WNhejSP6-D8VDjfu9ZNWZt6jHr98okcWj0kPHl7j8mf6x_3l7-WN3c_f19e3CxNSatpKUVnULZ1U3W1qGsrW81aUUMpuBRojW2MRtZg03VY2hYrDdDaSnZoubSUwjE53_qu53bEbOanqAe1jjl6fFFBO_Ve8a5Xq_CsKimBsyobnL4ZxPA0Y5rU6JLBYdAew5wUBwGiliAho1__Qx_CHH1eT3EhGy5Evpn6tqVMDClFtLswjKpNP2rTj3rtJ8Nf9uPv0H9twF-GeI2p</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>van de Donk, Pim P</creator><creator>Kist de Ruijter, Laura</creator><creator>Lub-de Hooge, Marjolijn N</creator><creator>Brouwers, Adrienne H</creator><creator>van der Wekken, Anthonie J</creator><creator>Oosting, Sjoukje F</creator><creator>Fehrmann, Rudolf Sn</creator><creator>de Groot, Derk Jan A</creator><creator>de Vries, Elisabeth Ge</creator><general>Ivyspring International Publisher Pty Ltd</general><general>Ivyspring International Publisher</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2020</creationdate><title>Molecular imaging biomarkers for immune checkpoint inhibitor therapy</title><author>van de Donk, Pim P ; Kist de Ruijter, Laura ; Lub-de Hooge, Marjolijn N ; Brouwers, Adrienne H ; van der Wekken, Anthonie J ; Oosting, Sjoukje F ; Fehrmann, Rudolf Sn ; de Groot, Derk Jan A ; de Vries, Elisabeth Ge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-95dce9b786d7577f9ba1b57345295efcf8cae18e8dde4fbe6a33bf69def29f003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - immunology</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Cytotoxicity</topic><topic>Data warehouses</topic><topic>FDA approval</topic><topic>Fractals</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - metabolism</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Medical research</topic><topic>Melanoma</topic><topic>Metabolism</topic><topic>Molecular Imaging - methods</topic><topic>Neoplasms - diagnostic imaging</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - therapy</topic><topic>Oncology</topic><topic>Patient Selection</topic><topic>Patients</topic><topic>Positron-Emission Tomography - methods</topic><topic>Review</topic><topic>T-Lymphocytes - immunology</topic><topic>Tomography</topic><topic>Tomography, Emission-Computed, Single-Photon - methods</topic><topic>Tumors</topic><topic>Working groups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van de Donk, Pim P</creatorcontrib><creatorcontrib>Kist de Ruijter, Laura</creatorcontrib><creatorcontrib>Lub-de Hooge, Marjolijn N</creatorcontrib><creatorcontrib>Brouwers, Adrienne H</creatorcontrib><creatorcontrib>van der Wekken, Anthonie J</creatorcontrib><creatorcontrib>Oosting, Sjoukje F</creatorcontrib><creatorcontrib>Fehrmann, Rudolf Sn</creatorcontrib><creatorcontrib>de Groot, Derk Jan A</creatorcontrib><creatorcontrib>de Vries, Elisabeth Ge</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Theranostics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van de Donk, Pim P</au><au>Kist de Ruijter, Laura</au><au>Lub-de Hooge, Marjolijn N</au><au>Brouwers, Adrienne H</au><au>van der Wekken, Anthonie J</au><au>Oosting, Sjoukje F</au><au>Fehrmann, Rudolf Sn</au><au>de Groot, Derk Jan A</au><au>de Vries, Elisabeth Ge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular imaging biomarkers for immune checkpoint inhibitor therapy</atitle><jtitle>Theranostics</jtitle><addtitle>Theranostics</addtitle><date>2020</date><risdate>2020</risdate><volume>10</volume><issue>4</issue><spage>1708</spage><epage>1718</epage><pages>1708-1718</pages><issn>1838-7640</issn><eissn>1838-7640</eissn><abstract>Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with
F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher Pty Ltd</pub><pmid>32042331</pmid><doi>10.7150/thno.38339</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1838-7640 |
| ispartof | Theranostics, 2020, Vol.10 (4), p.1708-1718 |
| issn | 1838-7640 1838-7640 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6993216 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Antibodies Apoptosis Biomarkers Biomarkers, Tumor - immunology Biomarkers, Tumor - metabolism Cancer Cytotoxicity Data warehouses FDA approval Fractals Humans Immune Checkpoint Inhibitors - metabolism Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Immunotherapy - methods Ligands Lymphocytes Lymphoma Medical research Melanoma Metabolism Molecular Imaging - methods Neoplasms - diagnostic imaging Neoplasms - immunology Neoplasms - pathology Neoplasms - therapy Oncology Patient Selection Patients Positron-Emission Tomography - methods Review T-Lymphocytes - immunology Tomography Tomography, Emission-Computed, Single-Photon - methods Tumors Working groups |
| title | Molecular imaging biomarkers for immune checkpoint inhibitor therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T03%3A07%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20imaging%20biomarkers%20for%20immune%20checkpoint%20inhibitor%20therapy&rft.jtitle=Theranostics&rft.au=van%20de%20Donk,%20Pim%20P&rft.date=2020&rft.volume=10&rft.issue=4&rft.spage=1708&rft.epage=1718&rft.pages=1708-1718&rft.issn=1838-7640&rft.eissn=1838-7640&rft_id=info:doi/10.7150/thno.38339&rft_dat=%3Cproquest_pubme%3E2598255255%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2598255255&rft_id=info:pmid/32042331&rfr_iscdi=true |